Benjamin J. Dunmore

Cambridge, ENG CB20XY, United Kingdom

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 25 publications

Interleukin-6 is critical in the development of pulmonary vascular disease in Gcn2-deficient mice.

Interleukin-6 is critical in the development of pulmonary vascular disease in Gcn2-deficient mice.

Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: July 06, 2026

Sotatercept reduces bone morphogenetic protein signaling in patients with pulmonary arterial hypertension.

Sotatercept reduces bone morphogenetic protein signaling in patients with pulmonary arterial hypertension.

Journal: Science translational medicine
Published: May 20, 2026

BMP9 knockout impairs pulmonary vessel muscularisation and confers aberrant tamoxifen sensitivity.

BMP9 knockout impairs pulmonary vessel muscularisation and confers aberrant tamoxifen sensitivity.

Journal: Angiogenesis
Published: April 01, 2025

Activin-A Regulates Bone Morphogenetic Protein Signaling in Pulmonary Endothelial Cells Without Affecting Bone Morphogenetic Protein Type-II Receptor Expression.

Activin-A Regulates Bone Morphogenetic Protein Signaling in Pulmonary Endothelial Cells Without Affecting Bone Morphogenetic Protein Type-II Receptor Expression.

Journal: Pulmonary circulation
Published: March 12, 2025

SEMA3G regulates BMP9 inhibition of VEGF-mediated migration and network formation in pulmonary endothelial cells.

SEMA3G regulates BMP9 inhibition of VEGF-mediated migration and network formation in pulmonary endothelial cells.

Journal: Vascular pharmacology
Published: February 26, 2024

Reduced circulating BMP9 and pBMP10 in hospitalized COVID-19 patients.

Reduced circulating BMP9 and pBMP10 in hospitalized COVID-19 patients.

Journal: Pulmonary circulation
Published: November 03, 2022

An organ-on-chip model of pulmonary arterial hypertension identifies a BMPR2-SOX17-prostacyclin signalling axis.

An organ-on-chip model of pulmonary arterial hypertension identifies a BMPR2-SOX17-prostacyclin signalling axis.

Journal: Communications biology
Published: May 04, 2022

An emerging class of new therapeutics targeting TGF, Activin, and BMP ligands in pulmonary arterial hypertension.

An emerging class of new therapeutics targeting TGF, Activin, and BMP ligands in pulmonary arterial hypertension.

Journal: Developmental dynamics : an official publication of the American Association of Anatomists
Published: December 02, 2021

The impact of hypoxia on B cells in COVID-19.

The impact of hypoxia on B cells in COVID-19.

Journal: EBioMedicine
Published: November 09, 2021

Longitudinal analysis reveals that delayed bystander CD8+ T cell activation and early immune pathology distinguish severe COVID-19 from mild disease.

Longitudinal analysis reveals that delayed bystander CD8+ T cell activation and early immune pathology distinguish severe COVID-19 from mild disease.

Journal: Immunity
Published: December 21, 2020

Approaches to treat pulmonary arterial hypertension by targeting BMPR2: from cell membrane to nucleus.

Approaches to treat pulmonary arterial hypertension by targeting BMPR2: from cell membrane to nucleus.

Journal: Cardiovascular research
Published: September 11, 2020

Targeting translational read-through of premature termination mutations in BMPR2 with PTC124 for pulmonary arterial hypertension.

Targeting translational read-through of premature termination mutations in BMPR2 with PTC124 for pulmonary arterial hypertension.

Journal: Pulmonary circulation
Published: April 28, 2020
Showing 1-12 of 25

Last Updated: 09/26/2026